INSIGHTS INTO DIAGNOSIS AND MANAGEMENT OF ADVANCED MULTIPLE MYELOMA

Objective: The advanced stages of multiple myeloma (MM) commonly manifest a recurrent evolution, unfavorable prognosis and negative socio-economic impact. The increased rates of morbidity and DALYs, frequent complications and relapses, unfavorable socio-economic impact characterize MM as an actual i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vasile Musteata, Nina Sghibneva-Bobeico, Doina Ranga, Larisa Musteata, Cristina Dudnic
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/3b8cb8fbe8504e4fb873f07df2cb2562
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3b8cb8fbe8504e4fb873f07df2cb2562
record_format	dspace
spelling	oai:doaj.org-article:3b8cb8fbe8504e4fb873f07df2cb25622021-11-10T04:36:22ZINSIGHTS INTO DIAGNOSIS AND MANAGEMENT OF ADVANCED MULTIPLE MYELOMA2531-137910.1016/j.htct.2021.10.1043https://doaj.org/article/3b8cb8fbe8504e4fb873f07df2cb25622021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921011901https://doaj.org/toc/2531-1379Objective: The advanced stages of multiple myeloma (MM) commonly manifest a recurrent evolution, unfavorable prognosis and negative socio-economic impact. The increased rates of morbidity and DALYs, frequent complications and relapses, unfavorable socio-economic impact characterize MM as an actual issue of hematology and public health. The objective of the study was the identification of diagnostic patterns and the evaluation of short- and long-term results of treatment of the advanced stages of MM. Methodology: The study is a cross-sectional descriptive analysis of a cohort of 50 newly diagnosed patients with advanced stages of MM, who have been treated and followed-up at the Hematology Dept. of the Oncology Institute from Moldova during 2016-2020. The diagnosis was assessed by cytological, immunohistochemical examinations of the bone tissue and bone marrow, and ELISA immunological test of the peripheral blood. The stage was asserted in each case according to the Revised International Staging System. Results: The patients age ranged between 28-75 years (median - 57.7 years). MM developed mainly in persons aged 60-69 (52%) years and in rare cases under 39 years (6%). Females were 29 (58%), and males - 21 (42%). 31 (62%) patients were diagnosed in stage III, 14 (28%) - in stage II and 5 (10%) - in stage I. Immunoglobulin (Ig) G isotype was detected in 28 (56%) cases, IgA - in 12 (24%), light chains (Bence Jones MM) - in 10 (20%). Very good partial responses were achieved in 25 (50%) of patients. Conclusion: MM was diagnosed mostly in patients of 60-69 years, females and stage III disease. Bone marrow myeloma cells ranged between 30-67% (median - 46%). Concerning the Ig isotype distribution in MM, IgG accounted the majority of cases. Refractory chronic renal failure was the most common complication (50% of cases) in advanced MM. Targeted chemotherapy proved to be efficient in the advanced stages of MM regardless of the gender, age and disease span. Very good partial responses lasted 12-24 months.Vasile MusteataNina Sghibneva-BobeicoDoina RangaLarisa MusteataCristina DudnicElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S45- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Vasile Musteata Nina Sghibneva-Bobeico Doina Ranga Larisa Musteata Cristina Dudnic INSIGHTS INTO DIAGNOSIS AND MANAGEMENT OF ADVANCED MULTIPLE MYELOMA
description	Objective: The advanced stages of multiple myeloma (MM) commonly manifest a recurrent evolution, unfavorable prognosis and negative socio-economic impact. The increased rates of morbidity and DALYs, frequent complications and relapses, unfavorable socio-economic impact characterize MM as an actual issue of hematology and public health. The objective of the study was the identification of diagnostic patterns and the evaluation of short- and long-term results of treatment of the advanced stages of MM. Methodology: The study is a cross-sectional descriptive analysis of a cohort of 50 newly diagnosed patients with advanced stages of MM, who have been treated and followed-up at the Hematology Dept. of the Oncology Institute from Moldova during 2016-2020. The diagnosis was assessed by cytological, immunohistochemical examinations of the bone tissue and bone marrow, and ELISA immunological test of the peripheral blood. The stage was asserted in each case according to the Revised International Staging System. Results: The patients age ranged between 28-75 years (median - 57.7 years). MM developed mainly in persons aged 60-69 (52%) years and in rare cases under 39 years (6%). Females were 29 (58%), and males - 21 (42%). 31 (62%) patients were diagnosed in stage III, 14 (28%) - in stage II and 5 (10%) - in stage I. Immunoglobulin (Ig) G isotype was detected in 28 (56%) cases, IgA - in 12 (24%), light chains (Bence Jones MM) - in 10 (20%). Very good partial responses were achieved in 25 (50%) of patients. Conclusion: MM was diagnosed mostly in patients of 60-69 years, females and stage III disease. Bone marrow myeloma cells ranged between 30-67% (median - 46%). Concerning the Ig isotype distribution in MM, IgG accounted the majority of cases. Refractory chronic renal failure was the most common complication (50% of cases) in advanced MM. Targeted chemotherapy proved to be efficient in the advanced stages of MM regardless of the gender, age and disease span. Very good partial responses lasted 12-24 months.
format	article
author	Vasile Musteata Nina Sghibneva-Bobeico Doina Ranga Larisa Musteata Cristina Dudnic
author_facet	Vasile Musteata Nina Sghibneva-Bobeico Doina Ranga Larisa Musteata Cristina Dudnic
author_sort	Vasile Musteata
title	INSIGHTS INTO DIAGNOSIS AND MANAGEMENT OF ADVANCED MULTIPLE MYELOMA
title_short	INSIGHTS INTO DIAGNOSIS AND MANAGEMENT OF ADVANCED MULTIPLE MYELOMA
title_full	INSIGHTS INTO DIAGNOSIS AND MANAGEMENT OF ADVANCED MULTIPLE MYELOMA
title_fullStr	INSIGHTS INTO DIAGNOSIS AND MANAGEMENT OF ADVANCED MULTIPLE MYELOMA
title_full_unstemmed	INSIGHTS INTO DIAGNOSIS AND MANAGEMENT OF ADVANCED MULTIPLE MYELOMA
title_sort	insights into diagnosis and management of advanced multiple myeloma
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/3b8cb8fbe8504e4fb873f07df2cb2562
work_keys_str_mv	AT vasilemusteata insightsintodiagnosisandmanagementofadvancedmultiplemyeloma AT ninasghibnevabobeico insightsintodiagnosisandmanagementofadvancedmultiplemyeloma AT doinaranga insightsintodiagnosisandmanagementofadvancedmultiplemyeloma AT larisamusteata insightsintodiagnosisandmanagementofadvancedmultiplemyeloma AT cristinadudnic insightsintodiagnosisandmanagementofadvancedmultiplemyeloma
_version_	1718440544607141888

INSIGHTS INTO DIAGNOSIS AND MANAGEMENT OF ADVANCED MULTIPLE MYELOMA

Ejemplares similares